PET10

PreclinicalSmall molecule

UUniversity of Aarhus

PET10 is one of 6 small molecule programs targeting Giant Cell Arteritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell ArteritisActive, not recruiting

Giant Cell ArteritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Giant Cell Arteritis

#DrugCompanyPhaseTrials

Actemra

CCelltrion

Approved

9 2

Orencia

Bristol-Myers Squibb

Phase 3

3 3

Trexall

Jazz Pharmaceuticals

Phase 3

3 4

Tracleer

Johnson & Johnson

Phase 2

1 5

Prednisone Treatment

CCentre Hospitalier Universitaire Dijon

Phase 3

2 6

PET10

UUniversity of Aarhus

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Giant Cell Arteritis1 trial

FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment

Completed·UUniversity of Aarhus··NCT03285945·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PET10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PET10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PET10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Aarhus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Aarhus

PET10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Giant Cell Arteritis1 trial

References

Drug Info

Quick Facts

Related News